CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 444 filers reported holding CRISPR THERAPEUTICS AG in Q1 2022. The put-call ratio across all filers is 0.99 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,830 | -19.8% | 40,000 | 0.0% | 0.00% | -20.0% |
| Q2 2023 | $2,281 | +158.3% | 40,000 | +100.0% | 0.01% | +150.0% |
| Q1 2023 | $883 | +5.0% | 20,000 | -4.0% | 0.00% | 0.0% |
| Q4 2022 | $841 | -99.9% | 20,843 | +4.2% | 0.00% | -50.0% |
| Q3 2022 | $1,304,000 | -54.7% | 20,000 | -56.2% | 0.00% | -50.0% |
| Q2 2022 | $2,877,000 | -1.7% | 45,660 | 0.0% | 0.01% | +14.3% |
| Q1 2022 | $2,926,000 | +8.4% | 45,660 | +29.9% | 0.01% | 0.0% |
| Q4 2021 | $2,699,000 | -51.8% | 35,160 | -30.8% | 0.01% | -56.2% |
| Q3 2021 | $5,599,000 | -17.0% | 50,810 | +13.4% | 0.02% | -20.0% |
| Q2 2021 | $6,744,000 | +61.2% | 44,810 | +23.4% | 0.02% | +42.9% |
| Q1 2021 | $4,183,000 | +62.5% | 36,310 | +122.6% | 0.01% | +40.0% |
| Q4 2020 | $2,574,000 | +125.2% | 16,310 | +21.3% | 0.01% | +100.0% |
| Q3 2020 | $1,143,000 | – | 13,450 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $32,581,000 | 55.55% |
| NEA Management Company, LLC | 1,590,002 | $103,907,000 | 5.19% |
| ARK Investment Management | 8,237,122 | $538,296,000 | 3.75% |
| Nikko Asset Management Americas, Inc. | 4,262,736 | $277,078,000 | 3.54% |
| CLOUGH CAPITAL PARTNERS L P | 414,767 | $27,105,000 | 2.89% |
| Integral Health Asset Management, LLC | 220,000 | $14,377,000 | 2.79% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,268,000 | 2.48% |
| HC Advisors, LLC | 53,944 | $3,525,000 | 2.43% |
| Green Alpha Advisors, LLC | 27,466 | $1,795,000 | 1.52% |
| EFG Asset Management (North America) Corp. | 84,356 | $5,516,000 | 1.28% |